Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Central Nervous System Infections: Advances and Challenges
Molecular Diagnosis & Therapy · 2024-09 · 28 (5) · 513-523
DOI: 10.1007/s40291-024-00727-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, online erschienen am 11.07.2024. Verfasst von LingHui David Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Metagenomics, Central Nervous System Infections. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Central nervous system (CNS) infections carry a substantial burden of morbidity and mortality worldwide, and accurate and timely diagnosis is required to optimize management. Metagenomic next-generation sequencing (mNGS) has proven to be a valuable tool in detecting pathogens in patients with suspected CNS infection. By sequencing microbial nucleic acids present in a patient's cerebrospinal fluid, brain tissue, or samples collected outside of the CNS, such as plasma, mNGS can detect a wide range of pathogens, including rare, unexpected, and/or fastidious organisms. Furthermore, its target-agnostic approach allows for the identification of both known and novel pathogens. This is particularly useful in cases where conventional diagnostic methods fail to provide an answer. In addition, mNGS can detect multiple microorganisms simultaneously, which is crucial in cases of mixed infections without a clear predominant pathogen. Overall, clinical mNGS testing can help expedite the diagnostic process for CNS infections, guide appropriate management decisions, and ultimately improve clinical outcomes. However, there are key challenges surrounding its use that need to be considered to fully leverage its clinical impact. For example, only a few specialized laboratories offer clinical mNGS due to the complexity of both the laboratory methods and analysis pipelines. Clinicians interpreting mNGS results must be aware of both false negatives-as mNGS is a direct detection modality and requires a sufficient amount of microbial nucleic acid to be present in the sample tested-and false positives-as mNGS detects environmental microbes and their nucleic acids, despite best practices to minimize contamination. Additionally, current costs and turnaround times limit broader implementation of clinical mNGS. Finally, there is uncertainty regarding the best practices for clinical utilization of mNGS, and further work is needed to define the optimal patient population(s), syndrome(s), and time of testing to implement clinical mNGS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
- The Consortium for Clinical Metagenomics in Infectious Diseases, Nashville, TN, USA.
- Department of Laboratory Medicine and Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Delve Bio, Inc., San Francisco, CA, USA.
ORCID-Profile: Anne Piantadosi
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Su, L. D., Chiu, C. Y., Gaston, D., Hogan, C. A., Miller, S., Simon, D. W., Thakur, K. T., Yang, S., & Piantadosi, A. (2024). Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Central Nervous System Infections: Advances and Challenges. Molecular Diagnosis & Therapy, 28(5), 513-523. https://doi.org/10.1007/s40291-024-00727-9
Vancouver
Su LD, Chiu CY, Gaston D, Hogan CA, Miller S, Simon DW, et al. Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Central Nervous System Infections: Advances and Challenges. Molecular Diagnosis & Therapy. 2024;28(5):513-523. doi:10.1007/s40291-024-00727-9
BibTeX
@article{Su2024,
author = {Su, LingHui David and Chiu, Charles Y and Gaston, David and Hogan, Catherine A and Miller, Steve and Simon, Dennis W and Thakur, Kiran T and Yang, Shangxin and Piantadosi, Anne},
title = {Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Central Nervous System Infections: Advances and Challenges},
journal = {Molecular Diagnosis & Therapy},
year = {2024},
volume = {28},
number = {5},
pages = {513--523},
doi = {10.1007/s40291-024-00727-9}
}
EUVIMED